Abstract
Three main targets were subjected for the most approved monoclonal antibodies (mAbs) in cancer therapy: EGFR in solid cancer, the clusters of differentiation in blood cancer and VEGF in angiogenesis. Meanwhile side effects, the elevated costs and resistance problems are limiting the efficiency of mAbs as targeted therapy. The combinatory therapy with chemo or radiotherapy has improved the efficiency of mAbs. The present review aims to shed more light on the immunotherapy and the related patents that were developed for cancer treatment.
Keywords: Cetuximab, Panitumumab, Nimutuzumab, trastuzumab, retuximab, ibritumumab, tozutumumab, ofamumumab, alemtuzumab, gemtuzumumab, Brentuximab, bevacizumab, ipilimumab, Neoplasms, immunotherapy, combinatory, United States Food and Drug Administration, patents.
Recent Patents on Biotechnology
Title:Monoclonal Antibodies as Cancer Therapeutics
Volume: 6 Issue: 1
Author(s): Jihene Elloumi, Karim Jellali, Ikram Jemel and Sami Aifa
Affiliation:
Keywords: Cetuximab, Panitumumab, Nimutuzumab, trastuzumab, retuximab, ibritumumab, tozutumumab, ofamumumab, alemtuzumab, gemtuzumumab, Brentuximab, bevacizumab, ipilimumab, Neoplasms, immunotherapy, combinatory, United States Food and Drug Administration, patents.
Abstract: Three main targets were subjected for the most approved monoclonal antibodies (mAbs) in cancer therapy: EGFR in solid cancer, the clusters of differentiation in blood cancer and VEGF in angiogenesis. Meanwhile side effects, the elevated costs and resistance problems are limiting the efficiency of mAbs as targeted therapy. The combinatory therapy with chemo or radiotherapy has improved the efficiency of mAbs. The present review aims to shed more light on the immunotherapy and the related patents that were developed for cancer treatment.
Export Options
About this article
Cite this article as:
Elloumi Jihene, Jellali Karim, Jemel Ikram and Aifa Sami, Monoclonal Antibodies as Cancer Therapeutics, Recent Patents on Biotechnology 2012; 6 (1) . https://dx.doi.org/10.2174/187220812799789190
DOI https://dx.doi.org/10.2174/187220812799789190 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of the Bone Marrow Microenvironment in Drug Resistance of
Hematological Malignances
Current Medicinal Chemistry Histone Deacetylase Inhibitors: An Attractive Strategy for Cancer Therapy
Current Medicinal Chemistry Serine-Threonine Protein Kinases CK1, CK2 and GSK3 in Normal and Malignant Haematopoiesis
Current Signal Transduction Therapy Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
Current Cancer Drug Targets Multiple Myeloma Bone Marrow Niche
Current Pharmaceutical Biotechnology Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued) Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Corticoisteroid-Induced Apoptosis in Hematological Malignancies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting of Hsp32 in Solid Tumors and Leukemias: A Novel Approach to Optimize Anticancer Therapy (Supplementry Material)
Current Cancer Drug Targets Natural Product as Substrates of ABC Transporters: A Review
Recent Patents on Anti-Cancer Drug Discovery Pharmacology and Therapeutic Applications of Enediyne Antitumor Antibiotics
Current Molecular Pharmacology Optimizing Gene Silencing Strategies for Pancreatic Cancer
Current Cancer Therapy Reviews Circumventing Melanoma Chemoresistance by Targeting DNA Repair
Current Medicinal Chemistry Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science Phytochemicals and Antioxidants: An Evaluation in Understanding the Human Lifeline
Current Nutrition & Food Science Endocrine and Antineoplastic Actions of Growth Hormone-Releasing Hormone Antagonists
Current Medicinal Chemistry Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death
Current Cancer Drug Targets